NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm OncoDNA said today that it has signed agreements with Gammaray Private Health Services and AMS 2000 Trading Impex to distribute OncoDNA's molecular profiling products in Turkey and Romania, respectively.
The agreements confirm the growing interest of OncoDNA's comprehensive molecular profiling solutions in Turkey and Romania, OncoDNA CEO Jean-Pol Detiffe said in a statement. "We anticipate a strong increase in the use of OncoDNA profiling products" in Europe, Detiffe added.
"Patients [will] benefit from the most suitable and effective treatment options available to them, while exposure to potentially ineffective therapies are reduced under the guidance of useful precision medicine reporting services such as OncoSHARE," Gammaray CEO Cengiz Gemici said in a statement.
OncoDNA's platform combines comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA, and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO.
The news comes after OncoDNA said earlier this month that the Spanish Society of Pathology and the Spanish Society of Medical Oncology have endorsed usage of the firm's genomic tools to identify cancers of unknown primary origin.